Apomorphine subcutaneous titration in Parkinson’s disease - the effectiveness and safety of apomorphine challenges: A Literature Review

Albanese, A., et al. (2001). “Consensus statement on the role of acute dopaminergic challenge in Parkinson’s disease.” 16(2): 197-201. Albanese A. ( 2001 ). “Consensus statement on the role of acute dopaminergic challenge in Parkinson’s disease.” 16 ( 2 ): 197 - 201 . Search in Google Scholar

Bhidayasiri, R., et al. (2015). “Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.” 38(3): 89-103. Bhidayasiri R. ( 2015 ). “Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.” 38 ( 3 ): 89 - 103 . Search in Google Scholar

Bhidayasiri, R., et al. (2016). “Practical management of adverse events related to apomorphine therapy.” Parkinsonism Relat Disord 33 Suppl 1: S42-S48. Bhidayasiri R. ( 2016 ). “Practical management of adverse events related to apomorphine therapy.” Parkinsonism Relat Disord 33 Suppl 1 : S42 - S48 . Search in Google Scholar

Brown, W., et al. (1999). FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology, 53(6), 1212-1212. Brown W. ( 1999 ). FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa . Neurology , 53 ( 6 ), 1212 - 1212 . Search in Google Scholar

Clarke, C., et al. (2000). “Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease.” 69(5): 590-594. Clarke C. ( 2000 ). “Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease.” 69 ( 5 ): 590 - 594 . Search in Google Scholar

Colosimo, C., Martínez‐Martín, P., Fabbrini, G., Hauser, R. A., Merello, M., Miyasaki, J., ... & Schrag, A. (2010). “Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations.” Movement Disorders, 25(9): 1131-1142. Colosimo C. Martínez-Martín P. Fabbrini G. Hauser R. A. Merello M. Miyasaki J. Schrag A. ( 2010 ). “Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations.” Movement Disorders , 25 ( 9 ): 1131 - 1142 . Search in Google Scholar

Colzi, A., et al. (1998). “Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease.” 64(5): 573-576. Colzi A. ( 1998 ). “Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease.” 64 ( 5 ): 573 - 576 . Search in Google Scholar

Deleu, D., et al. (2004). “Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease.” 21(11): 687-709. Deleu D. ( 2004 ). “Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease.” 21 ( 11 ): 687 - 709 . Search in Google Scholar

Factor, S. A. J. N. (2004). “Literature review: intermittent subcutaneous apomorphine therapy in Parkinson’s disease.” 62(6 suppl 4): S12-S17. Factor S. A. J. N. ( 2004 ). “Literature review: intermittent subcutaneous apomorphine therapy in Parkinson’s disease.” 62 ( 6 suppl 4 ): S12 - S17 . Search in Google Scholar

Frankel, J., et al. (1990). “Subcutaneous apomorphine in the treatment of Parkinson’s disease.” 53(2): 96-101. Frankel J. ( 1990 ). “Subcutaneous apomorphine in the treatment of Parkinson’s disease.” 53 ( 2 ): 96 - 101 . Search in Google Scholar

Hauser, R. A., et al. (2004). “Parkinson’s disease home diary: further validation and implications for clinical trials.” 19(12): 1409-1413. Hauser R. A. ( 2004 ). “Parkinson’s disease home diary: further validation and implications for clinical trials.” 19 ( 12 ): 1409 - 1413 . Search in Google Scholar

Isaacson, S., et al. (2016). “Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson’s disease.” 4(1): 78-83. Isaacson S. ( 2016 ). “Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson’s disease.” 4 ( 1 ): 78 - 83 . Search in Google Scholar

Jenner, P. and R. Katzenschlager (2016). “Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease.” Parkinsonism Relat Disord 33 Suppl 1: S13-S21. Jenner P. Katzenschlager R. ( 2016 ). “Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease.” Parkinsonism Relat Disord 33 Suppl 1 : S13 - S21 . Search in Google Scholar

Katzenschlager, R., et al. (2018). “Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multi-centre, double-blind, randomised, placebo-controlled trial.” 17(9): 749-759. Katzenschlager R. ( 2018 ). “Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multi-centre, double-blind, randomised, placebo-controlled trial.” 17 ( 9 ): 749 - 759 . Search in Google Scholar

Mitchell, A. J. (2013). The Mini-Mental State Examination (MMSE): an update on its diagnostic validity for cognitive disorders. Cognitive screening instruments, Springer: 15-46. Mitchell A. J. ( 2013 ). The Mini-Mental State Examination (MMSE): an update on its diagnostic validity for cognitive disorders. Cognitive screening instruments , Springer : 15 - 46 . Search in Google Scholar

Muguet, D., et al. (1995). “Apomorphine in patients with Parkinson’s disease.” 49(4): 197-209. Muguet D. ( 1995 ). “Apomorphine in patients with Parkinson’s disease.” 49 ( 4 ): 197 - 209 . Search in Google Scholar

NICE (2017). “Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care.” NICE ( 2017 ). “Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care.” Search in Google Scholar

Ondo, W. G., et al. (2012). “Apomorphine injections: predictors of initial common adverse events and long term tolerability.” Parkinsonism Relat Disord 18(5): 619-622. Ondo W. G. ( 2012 ). “Apomorphine injections: predictors of initial common adverse events and long term tolerability.” Parkinsonism Relat Disord 18 ( 5 ): 619 - 622 . Search in Google Scholar

Ostergaard, L., et al. (1995). “Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study.” 58(6): 681-687. Ostergaard L. ( 1995 ). “Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study.” 58 ( 6 ): 681 - 687 . Search in Google Scholar

Pahwa, R., et al. (2007). “Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.” 258(1-2): 137-143. Pahwa R. ( 2007 ). “Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.” 258 ( 1-2 ): 137 - 143 . Search in Google Scholar

Papapetropoulos, Spyridon. (2011). Patient Diaries As a Clinical Endpoint in Parkinson’s Disease Clinical Trials. CNS neuroscience & therapeutics. 18. 380-7. 10.1111/j.1755-5949.2011.00253.x. Papapetropoulos Spyridon . ( 2011 ). Patient Diaries As a Clinical Endpoint in Parkinson’s Disease Clinical Trials . CNS neuroscience & therapeutics . 18 . 380 - 7 . 10.1111/j.1755-5949.2011.00253.x . Open DOISearch in Google Scholar

Perez-Lloret, S. and O. J. C. d. Rascol (2010). “Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease.” 24(11): 941-968. Perez-Lloret S. Rascol O. J. C. d. ( 2010 ). “Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease.” 24 ( 11 ): 941 - 968 . Search in Google Scholar

Pfeiffer, R. F., et al. (2007). “Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease.” Parkinsonism Relat Disord 13(2): 93-100. Pfeiffer R. F. ( 2007 ). “Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease.” Parkinsonism Relat Disord 13 ( 2 ): 93 - 100 . Search in Google Scholar

Pietz, K., et al. (1998). “Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up.” 65(5): 709-716. Pietz K. ( 1998 ). “Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up.” 65 ( 5 ): 709 - 716 . Search in Google Scholar

Price, J., et al. (2016). “A case series of rapid titration of subcutaneous apomorphine in Parkinson’s disease.” 12(2): 70-74. Price J. ( 2016 ). “A case series of rapid titration of subcutaneous apomorphine in Parkinson’s disease.” 12 ( 2 ): 70 - 74 . Search in Google Scholar

Sesar, Á., et al. (2017). “Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients.” 264(5): 946-954. Sesar Á. ( 2017 ). “Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients.” 264 ( 5 ): 946 - 954 . Search in Google Scholar

Setter, S. M. J. N. c. (2008). “Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson’s disease.” 26(3): 45-63. Setter S. M. J. N. c. ( 2008 ). “Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson’s disease.” 26 ( 3 ): 45 - 63 . Search in Google Scholar

Tomlinson, C. L., et al. (2010). “Systematic review of levodopa dose equivalency reporting in Parkinson’s disease.” 25(15): 2649-2653. Tomlinson C. L. ( 2010 ). “Systematic review of levodopa dose equivalency reporting in Parkinson’s disease.” 25 ( 15 ): 2649 - 2653 . Search in Google Scholar

Trenkwalder, C., et al. (2015). “Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease –clinical practice recommendations.” 21(9): 1023-1030. Trenkwalder C. ( 2015 ). “Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease –clinical practice recommendations.” 21 ( 9 ): 1023 - 1030 . Search in Google Scholar

van Laar, T. and R. Borgemeester (2016). “The need for non-oral therapy in Parkinson’s disease; a potential role for apomorphine.” Parkinsonism Relat Disord 33 Suppl 1: S22-S27. van Laar T. Borgemeester R. ( 2016 ). “The need for non-oral therapy in Parkinson’s disease; a potential role for apomorphine.” Parkinsonism Relat Disord 33 Suppl 1 : S22 - S27 . Search in Google Scholar